FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588070030> ?p ?o ?g. }

• W2588070030 abstract "Abstract Abstract 4603 Background: The clinical course of patients with chronic lymphocytic leukemia (CLL) is remarkably heterogeneous. All CLL patients who require therapy are destined to relapse. The prognosis and management of these relapsed patients differs based on the nature of the first-line therapy and the quality and duration of remission to that therapy, as well as biological prognostic factors. Currently, the first treatment option for younger and fit CLL patients is FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy. Although it regards a very potent treatment option, patients inevitably relapse after the treatment and even approximately 7% of the patients, during initial FCR regimen treatment would fit the standard definition of refractory CLL. So far, little is known about the efficacy of subsequent therapy of patients who relapsed after FCR or were refractory to FCR. Therefore, the goal of this study was to analyze the fate of these patients in the context of routine hematological practice. Methods: We retrospectively analyzed the data of 119 patients (85 males; 34 females) consecutively entered into the databases of three large tertiary Czech hematological centers. All patients were indicated to receive FCR regimen in standard doses (F: 25mg/m2i.v. day 1–3; C: 250mg/m2i.v. day 1–3; R: 375mg/m2i.v.day 0 cycle 1, and 500mg/m2day 1 of all subsequent cycles). Results: The median age was 57 years (range, 31–75) at the time of the CLL diagnosis, and 60 years (range, 32–78) at the start of FCR therapy. The median follow-up was 42 months (range, 3–114). Our cohort of patients consisted of two groups of patients which received the FCR regimen as first-line therapy (Group 1; n=63) and patients receiving FCR in second or subsequent line of treatment (Group 2; n=56). With respect to the basic parameters (age, clinical stage, FISH cytogenetics, molecular genetics), the statistics of these groups did not differ significantly. In Group 1, the overall response rate (ORR) was 84%, in Group 2, 78% (p=ns) after FCR. Complete remission (CR) rate was 53% in Group 1, and 38% in Group 2 (p=0.04). The median progression-free survival (PFS) was 18.6 months for Group 1 and 14.7 months for Group 2 (p=ns). With subsequent therapy (repeated FCR, alemtuzumab, R-CHOP, rituximab plus high-dose corticosteroids) for relapsed disease after FCR, ORR was 59% in Group 1 (33% CR) and 44% in Group 2 (21% CR) (p=ns). PFS after subsequent therapy after FCR was 13.3 months (Group 1) and 5.9 months (Group 2) (p=0.01). The median OS was insignificantly shorter in Group 2 (44.5 months in Group 2 vs. not reached in Group 1; p=ns). After FCR therapy, there was no statistically significant change in cytogenetic findings, however, new occurrence of 17p deletion was observed in 5 patients. Prior to FCR therapy and during relapse after FCR, the p53 function was analyzed in 37 patients. After FCR, the new mutation of p53 was newly found in 6 patients (16%). These patients received a higher cumulative dose of FCR than the patients who did not develop the mutation (F 591 mg vs. 334 mg; C 5072 mg vs. 3375mg; R 3700mg vs. 2000 mg) (p=ns). Conclusion: Subsequent treatment for patients who relapse after FCR or are FCR refractory is very heterogeneous. Regardless of the type of therapy selected, the prognosis of these patients is poor. In addition, new p53 mutations/deletions occur after FCR. Disclosures: No relevant conflicts of interest to declare." @default.
• W2588070030 created "2017-02-24" @default.
• W2588070030 creator A5038787111 @default.
• W2588070030 creator A5042672780 @default.
• W2588070030 creator A5049999011 @default.
• W2588070030 creator A5054654885 @default.
• W2588070030 creator A5060862358 @default.
• W2588070030 creator A5064699040 @default.
• W2588070030 creator A5065520471 @default.
• W2588070030 creator A5068758499 @default.
• W2588070030 creator A5071015212 @default.
• W2588070030 creator A5077793241 @default.
• W2588070030 creator A5079245416 @default.
• W2588070030 creator A5090624182 @default.
• W2588070030 date "2012-11-16" @default.
• W2588070030 modified "2023-10-18" @default.
• W2588070030 title "The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen" @default.
• W2588070030 doi "https://doi.org/10.1182/blood.v120.21.4603.4603" @default.
• W2588070030 hasPublicationYear "2012" @default.
• W2588070030 type Work @default.
• W2588070030 sameAs 2588070030 @default.
• W2588070030 citedByCount "0" @default.
• W2588070030 crossrefType "journal-article" @default.
• W2588070030 hasAuthorship W2588070030A5038787111 @default.
• W2588070030 hasAuthorship W2588070030A5042672780 @default.
• W2588070030 hasAuthorship W2588070030A5049999011 @default.
• W2588070030 hasAuthorship W2588070030A5054654885 @default.
• W2588070030 hasAuthorship W2588070030A5060862358 @default.
• W2588070030 hasAuthorship W2588070030A5064699040 @default.
• W2588070030 hasAuthorship W2588070030A5065520471 @default.
• W2588070030 hasAuthorship W2588070030A5068758499 @default.
• W2588070030 hasAuthorship W2588070030A5071015212 @default.
• W2588070030 hasAuthorship W2588070030A5077793241 @default.
• W2588070030 hasAuthorship W2588070030A5079245416 @default.
• W2588070030 hasAuthorship W2588070030A5090624182 @default.
• W2588070030 hasConcept C121332964 @default.
• W2588070030 hasConcept C126322002 @default.
• W2588070030 hasConcept C141071460 @default.
• W2588070030 hasConcept C142424586 @default.
• W2588070030 hasConcept C143998085 @default.
• W2588070030 hasConcept C151730666 @default.
• W2588070030 hasConcept C2776694085 @default.
• W2588070030 hasConcept C2776755627 @default.
• W2588070030 hasConcept C2777938653 @default.
• W2588070030 hasConcept C2778461978 @default.
• W2588070030 hasConcept C2779015954 @default.
• W2588070030 hasConcept C2779263901 @default.
• W2588070030 hasConcept C2779338263 @default.
• W2588070030 hasConcept C2779343474 @default.
• W2588070030 hasConcept C2780653079 @default.
• W2588070030 hasConcept C2780790343 @default.
• W2588070030 hasConcept C2781413609 @default.
• W2588070030 hasConcept C2911091166 @default.
• W2588070030 hasConcept C71924100 @default.
• W2588070030 hasConcept C86803240 @default.
• W2588070030 hasConcept C87355193 @default.
• W2588070030 hasConcept C90924648 @default.
• W2588070030 hasConceptScore W2588070030C121332964 @default.
• W2588070030 hasConceptScore W2588070030C126322002 @default.
• W2588070030 hasConceptScore W2588070030C141071460 @default.
• W2588070030 hasConceptScore W2588070030C142424586 @default.
• W2588070030 hasConceptScore W2588070030C143998085 @default.
• W2588070030 hasConceptScore W2588070030C151730666 @default.
• W2588070030 hasConceptScore W2588070030C2776694085 @default.
• W2588070030 hasConceptScore W2588070030C2776755627 @default.
• W2588070030 hasConceptScore W2588070030C2777938653 @default.
• W2588070030 hasConceptScore W2588070030C2778461978 @default.
• W2588070030 hasConceptScore W2588070030C2779015954 @default.
• W2588070030 hasConceptScore W2588070030C2779263901 @default.
• W2588070030 hasConceptScore W2588070030C2779338263 @default.
• W2588070030 hasConceptScore W2588070030C2779343474 @default.
• W2588070030 hasConceptScore W2588070030C2780653079 @default.
• W2588070030 hasConceptScore W2588070030C2780790343 @default.
• W2588070030 hasConceptScore W2588070030C2781413609 @default.
• W2588070030 hasConceptScore W2588070030C2911091166 @default.
• W2588070030 hasConceptScore W2588070030C71924100 @default.
• W2588070030 hasConceptScore W2588070030C86803240 @default.
• W2588070030 hasConceptScore W2588070030C87355193 @default.
• W2588070030 hasConceptScore W2588070030C90924648 @default.
• W2588070030 hasLocation W25880700301 @default.
• W2588070030 hasOpenAccess W2588070030 @default.
• W2588070030 hasPrimaryLocation W25880700301 @default.
• W2588070030 hasRelatedWork W2001453633 @default.
• W2588070030 hasRelatedWork W2085074066 @default.
• W2588070030 hasRelatedWork W2120141541 @default.
• W2588070030 hasRelatedWork W2278221429 @default.
• W2588070030 hasRelatedWork W2348637346 @default.
• W2588070030 hasRelatedWork W2556454004 @default.
• W2588070030 hasRelatedWork W2559375949 @default.
• W2588070030 hasRelatedWork W2563677510 @default.
• W2588070030 hasRelatedWork W2564158403 @default.
• W2588070030 hasRelatedWork W2570365985 @default.
• W2588070030 hasRelatedWork W2571883057 @default.
• W2588070030 hasRelatedWork W2573121531 @default.
• W2588070030 hasRelatedWork W2575619275 @default.
• W2588070030 hasRelatedWork W2590154459 @default.
• W2588070030 hasRelatedWork W2592936762 @default.
• W2588070030 hasRelatedWork W2593255448 @default.
• W2588070030 hasRelatedWork W2810037575 @default.
• W2588070030 hasRelatedWork W2979753510 @default.

• next